NCT06655662View on ClinicalTrials.gov

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Β-thalassemia
Interventions
OTHER

β-globin restored autologous hematopoietic stem cells

Eight transfusion-dependent β-thalassaemia subjects aged 6-35 years will be reinfused with β-globin restored autologous hematopoietic stem cells modified with LentiHBBT87Q

Trial Locations (3)

Unknown

RECRUITING

Guangxi Medical University First Affiliated Hospital, Guangxi

RECRUITING

Shenzhen Children's Hospital, Shenzhen

RECRUITING

Shenzhen University General Hospital, Shenzhen

All Listed Sponsors
lead

Shenzhen Hemogen

INDUSTRY